Medical Aesthetics Ad Compliance: 10 High-Risk Claims to Avoid in 2026
Superlatives, efficacy guarantees, price baiting — a practical guide to the 10 most common violations in medical aesthetics advertising, with rewrite strategies and a platform-by-platform review comparison.
Marketing teams at aesthetic clinics race against two clocks: content velocity, and the tightening of platform review and regulatory enforcement. China's Advertising Law, the Medical Advertising Administration Measures, and each platform's community rules form an ever-changing rule net — one careless sentence can trigger throttling, takedowns, or administrative penalties.
Based on the highest-frequency rules in the Medcxy compliance database, here are the 10 most common high-risk claim types.
1. Superlatives
"The most advanced", "No.1", "world-leading" — explicitly banned by Article 9 of the Advertising Law. Rewrite: replace evaluative claims with verifiable facts such as registration numbers and approval dates.
2. Efficacy guarantees
"100% effective", "permanent results", "refund if it doesn't work" are classic efficacy promises. Outcomes vary by individual; any guarantee is a violation.
3. Cure/efficacy rates
"99% success rate" rarely has a compliant source, and citing studies in advertising contexts is tightly restricted.
4. Before/after imagery
Patient comparisons require written consent, and most platforms restrict "results comparison" content separately.
5. Price baiting
"Was ¥3,980, now ¥99" and "price goes up tomorrow" risk price-fraud findings and platform marketing limits.
6. Inflated titles
"National-level expert", "most authoritative clinic" — titles must match practice registration records.
7. Celebrity association
"Celebrity's choice" implies endorsement; medical ads may not use endorsers.
8. Appearance anxiety
Platform rules (notably Xiaohongshu and Douyin) restrict narratives that manufacture appearance anxiety.
9. Off-label promotion
Products may only be promoted within NMPA-approved indications.
10. Missing credentials
Medical ads must trace back to an approved Medical Advertising Review Certificate; platforms additionally require the institution's practice license information.
Platform review comparison
| Dimension | Xiaohongshu | Douyin | |
|---|---|---|---|
| Before/after | Strictly limited | Strictly limited | Relatively lenient for official accounts |
| Price marketing | Restricted phrasing | Requires compliance components | Report-driven |
| Doctor-led content | Education OK, no funneling | Verification + allowlist | In-depth education allowed |
Shift compliance left with AI
These rules keep changing — which is exactly why Medcxy's compliance review module exists: sentence-by-sentence review, citations to specific statutes and platform clauses, and compliant rewrites, covering mainland China plus US/UK/EU/AU/JP/KR jurisdictions.
Compiled from public regulations and platform rules; not legal advice.
Medcxy: sentence-level compliance review · cross-border regulatory comparison · vertical knowledge Q&A.
Start for free